These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 29708235)

  • 21. The immunology of Leishmania infection and the implications for vaccine development.
    Vanloubbeeck Y; Jones DE
    Ann N Y Acad Sci; 2004 Oct; 1026():267-72. PubMed ID: 15604504
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Efstathiou A; Smirlis D
    Microorganisms; 2021 Mar; 9(4):. PubMed ID: 33801655
    [No Abstract]   [Full Text] [Related]  

  • 23. Virulence factors of Leishmania parasite: Their paramount importance in unraveling novel vaccine candidates and therapeutic targets.
    Kumari D; Mahajan S; Kour P; Singh K
    Life Sci; 2022 Oct; 306():120829. PubMed ID: 35872004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leishmaniasis Vaccine: Where are We Today?
    Kedzierski L
    J Glob Infect Dis; 2010 May; 2(2):177-85. PubMed ID: 20606974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leishmaniasis.
    Herwaldt BL
    Lancet; 1999 Oct; 354(9185):1191-9. PubMed ID: 10513726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetically modified live attenuated vaccine: A potential strategy to combat visceral leishmaniasis.
    Pandey SC; Kumar A; Samant M
    Parasite Immunol; 2020 Sep; 42(9):e12732. PubMed ID: 32418227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alternative to Chemotherapy-The Unmet Demand against Leishmaniasis.
    Didwania N; Shadab M; Sabur A; Ali N
    Front Immunol; 2017; 8():1779. PubMed ID: 29312309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leishmaniasis.
    Pace D
    J Infect; 2014 Nov; 69 Suppl 1():S10-8. PubMed ID: 25238669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The History of Live Attenuated
    Volpedo G; Bhattacharya P; Gannavaram S; Pacheco-Fernandez T; Oljuskin T; Dey R; Satoskar AR; Nakhasi HL
    Pathogens; 2022 Apr; 11(4):. PubMed ID: 35456106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice.
    Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK
    East Afr Med J; 2001 Feb; 78(2):90-2. PubMed ID: 11682953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunity to visceral leishmaniasis using genetically defined live-attenuated parasites.
    Selvapandiyan A; Dey R; Gannavaram S; Lakhal-Naouar I; Duncan R; Salotra P; Nakhasi HL
    J Trop Med; 2012; 2012():631460. PubMed ID: 21912560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interactions between Leishmania parasite and sandfly: a review.
    Tom A; Kumar NP; Kumar A; Saini P
    Parasitol Res; 2023 Dec; 123(1):6. PubMed ID: 38052752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Leishmaniasis: prevention, parasite detection and treatment.
    Kobets T; Grekov I; Lipoldova M
    Curr Med Chem; 2012; 19(10):1443-74. PubMed ID: 22360481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular epidemiology of leishmaniasis in Asia (focus on cutaneous infections).
    Katakura K
    Curr Opin Infect Dis; 2009 Apr; 22(2):126-30. PubMed ID: 19276879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identifying vaccine targets for anti-leishmanial vaccine development.
    Sundar S; Singh B
    Expert Rev Vaccines; 2014 Apr; 13(4):489-505. PubMed ID: 24606556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of host genetics in leishmaniasis.
    Sakthianandeswaren A; Foote SJ; Handman E
    Trends Parasitol; 2009 Aug; 25(8):383-91. PubMed ID: 19617002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cutaneous leishmaniasis: progress towards a vaccine.
    Launois P; Tacchini-Cottier F; Kieny MP
    Expert Rev Vaccines; 2008 Oct; 7(8):1277-87. PubMed ID: 18844599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Independent Circulation of
    Abbas MAS; Lachheb J; Chelbi I; Louati D; Dachraoui K; Ben Miled S; Zhioua E
    Pathogens; 2022 Jul; 11(8):. PubMed ID: 36014976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent developments in leishmaniasis.
    Melby PC
    Curr Opin Infect Dis; 2002 Oct; 15(5):485-90. PubMed ID: 12686880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunoregulatory mechanisms and CD4-CD8- (double negative) T cell subpopulations in human cutaneous leishmaniasis: a balancing act between protection and pathology.
    Gollob KJ; Antonelli LR; Faria DR; Keesen TS; Dutra WO
    Int Immunopharmacol; 2008 Oct; 8(10):1338-43. PubMed ID: 18687296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.